ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,229.99
-1.19%
Dow Jones
42,063.36
0.09%
Gold vs US Dollar
2,622.30
0.00%
Brent Oil
74.135
0.00%
Bitcoin
63,161.77
-0.07%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Avadel Pharmaceuticals PLC (AVDL)

  7. Avadel Pharmaceuticals PLC (AVDL) News

Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AVDL
DateTimeSourceHeadlineSymbolCompany
16/09/202422:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
13/09/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/09/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
12/09/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
03/09/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)NASDAQ:AVDLAvadel Pharmaceuticals PLC
28/08/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:AVDLAvadel Pharmaceuticals PLC
28/08/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
20/08/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral SuspensionNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202414:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202412:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
08/08/202412:00GlobeNewswire Inc.Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202421:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202421:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202421:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202421:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
01/08/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8NASDAQ:AVDLAvadel Pharmaceuticals PLC
31/07/202421:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
31/07/202421:05GlobeNewswire Inc.Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic HypersomniaNASDAQ:AVDLAvadel Pharmaceuticals PLC
27/06/202421:05GlobeNewswire Inc.Avadel Pharmaceuticals to Join Russell 3000® IndexNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202412:25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202412:17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVDLAvadel Pharmaceuticals PLC
18/06/202412:11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AVDLAvadel Pharmaceuticals PLC
30/05/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:AVDLAvadel Pharmaceuticals PLC
22/05/202413:00GlobeNewswire Inc.Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024NASDAQ:AVDLAvadel Pharmaceuticals PLC
21/05/202422:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
21/05/202422:27Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AVDLAvadel Pharmaceuticals PLC
21/05/202412:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVDLAvadel Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:AVDL

Your Recent History

LSE
VAST
Vast Resources
LSE
ALTN
Altyngold
LSE
SBTX
Skinbiotherapeutics
LSE
SYME
Supply@me Capital
LSE
ZED
Zenova
LSE
ENET
Ethernity Networks
LSE
QBT
Quantum Blockchain Techn...
LSE
BOO
Boohoo
LSE
BIRD
Blackbird
LSE
LLOY
Lloyds Banking
LSE
POS
Plexus
LSE
PANR
Pantheon Resources
LSE
SOLG
Solgold
LSE
THG
Thg
LSE
CZN
Curzon Energy
LSE
FXPO
Ferrexpo
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved